2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2020-03-28 |
|
2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2020-03-28 ±³À°ÀÏÀÚ : 2020-03-28 ±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ Á¦2 Àü½ÃÀå ±³À°ÁÖÁ¦ : 2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç¥ÀûÄ¡·á¿¬±¸È¸ ´ã´çÀÚ : ½É¹Î°æ ¿¬¶ôó : 02-741-8540 À̸ÞÀÏ : kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú, ÇÙÀÇÇаú Âü¼®¿¹»óÀοø : 100¸í Èñ¸ÁÆòÁ¡ : 3Á¡ Áö¿ª : ºÎ»ê±¤¿ª½Ã ±³À°½Ã°£ : 3 ½Ã°£ 50ºÐ ¼¼ºÎ¼ö°·á : 80,000¿ø ºñ°í ȸ¿ø - »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 60,000¿øºñȸ¿ø »çÀüµî·Ï 70,000¿ø ÇöÀåµî·Ï 80,000¿ø ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 12:00~12:40 Nivolumab, 5 year OS outcome of CheckMate 017/057 and real world outcome in Korea ±è¹ÌÇö(ºÎ»êÀÇ´ë) ÈÞ½Ä 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 12:40~13:00 ÈÞ½Ä () ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:00~13:20 Hyperprogression or pseudoprogression in immune checkpoint inhibitor treatment, that is the question ¹Úö±Ô(Àü³²ÀÇ´ë) ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:20~13:40 Updates of clinical and biomarkers for immune check point inhibitors treating NSCLC À¯½Â¼ö(°æºÏÀÇ´ë) ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:40~14:00 Drug agonistic acquired resistance in target therapy, is that a clue for outcome improvement? À±¼ºÈÆ(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:00~14:20 Sequential treatment issues of target therapy in EGFR or ALK+ NSCLC À̽ÂÇö(°æÈñÀÇ´ë) Åä·Ð 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:20~14:30 Åä·Ð () ÈÞ½Ä 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:30~15:00 ÈÞ½Ä () ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:00~15:20 Pathogenesis, clinicopathologic feature, and diagnosis of NTRK fusion+ NSCLC ±èÅÂÁ¤(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:20~15:40 Treatment of NTRK fusion+ NSCLC À̸í±Ô(¿¬¼¼ÀÇ´ë) Åä·Ð 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:40~15:50 Åä·Ð () ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:50~16:10 Emerging target agents for KRAS+ NSCLC ±èÀξÖ(°Ç±¹ÀÇ´ë) ±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 16:10~16:30 Efficacy of immune check point inhibitors for KRAS+ NSCLC ¹ÚÁö¿µ(ÇѸ²ÀÇ´ë) Åä·Ð 03-28 16:30~16:40 Åä·Ð () |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|
Á¦¸ñ |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 454 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 811 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 532 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 473 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 608 , ´ñ±Û¼ö : 0 |